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Abstract 
Background: Mantle cell lymphoma (MCL) is considered an aggressive subtype of non-Hodgkin’s lymphoma with 
variable treatment responses. There is an urgent need to identify novel markers with prognostic and therapeutic value 
for MCL. Long non-coding RNAs (lncRNAs) have emerged as key regulators in cancers, including MCL. Metastasis-
associated lung adenocarcinoma transcript 1(MALAT1), a lncRNA located at pathognomonic translocation site of t 
(11; 14) of MCL. MALAT1 is known to be overexpressed in solid tumors and hematologic malignancies. However, the 
pathological role and clinical relevance of MALAT1 in MCL are not completely understood.
Methods: We quantified MALAT1 in MCL samples (40) and CD19+ B cells by quantitative real time polymerase chain 
reaction (qRT-PCR) and correlated levels with clinical outcome. We silenced MALAT1 in MCL cell lines and analyzed 
cells in tumorigenic assays and formation of transcription complexes.
Results: We found that the expression of MALAT1 was elevated in human MCL tumors and cell lines as compared to 
normal controls, and the elevated levels of MALAT1 correlated with higher MCL international prognostic index (MIPI) 
and reduced overall survival. MCL with knockdown of MALAT1 showed impaired cell proliferation, facilitated apop-
tosis and produced fewer clonogenic foci. The increased expression of p21 and p27 upon MALAT1 knockdown was 
regulated by enhancer of zeste homolog 2 (EZH2). Moreover, decreased phosphorylation of EZH2 at T350 attenuated 
the binding to MALAT1.
Conclusions: Our findings illuminate the oncogenic role of MALAT1, which may serve as a novel biomarker and as a 
therapeutic target in MCL.
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Background
With an annual incidence of 0.5 per 100,000 populations 
in Western countries, mantle cell lymphoma (MCL) is an 
aggressive subtype of non-Hodgkin’s lymphoma (NHL), 
comprising about 6% of NHL cases [1]. Despite an ini-
tial therapeutic response, patients consistently develop 
recurrence and chemoresistance [2]. Moreover, elderly 
patients with MCL do not tolerate the toxicities of chem-
otherapy. Thus, there is a substantial need to identify 
novel markers for prognosis and explore alternative ther-
apies for MCL patients.
Over half of the human genome is actively transcribed 
as noncoding RNAs [3]. The noncoding transcripts that 
are more than 200 nucleotides in length are termed long 
noncoding RNAs (lncRNAs). lncRNAs have been recog-
nized to play important roles in pathologic conditions, 
such as cancer [4, 5]. It has been demonstrated that lncR-
NAs influence tumor progression through modulating 
cell cycle, survival, immune response or pluripotency, 
through their interactions with DNA, protein, and RNA 
[6, 7].
Recent studies in lymphoma have shown that lncRNA 
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interaction with RBM5, in order to produce membrane 
associated Fas or decoy soluble Fas [8]. In addition, 
expression of lncRNAs (PEG10, LUNAR1 and HULC) 
is correlated with clinical poor prognosis in diffuse large 
B cell lymphoma (DLBCL). Reduced expression of these 
same lncRNAs inhibited cell proliferation of DLBCL 
in  vitro [9–11]. Additional lncRNAs have been discov-
ered to regulate oncogenic process in lymphomas. For 
example, Verma Asyu et  al. examined RNA-seq data 
from primary DLBCL tumors and identified 2632 novel 
lncRNAs, which are implicated to interact with EZH2, 
H3K4me3, NFκB and STAT3 [12]. Another study using 
microarray analysis reported 189 lncRNAs that were 
significantly dysregulated in follicular lymphoma (FL), 
which are related to the TNF signaling and virus related 
carcinogenesis [13].
Metastasis-associated lung adenocarcinoma transcript 
1(MALAT1) is an evolutionarily conserved, long non-
coding RNA 8.7  kb transcript, located on chromosome 
11q13, a site in vicinity of t (11;14) of MCL. Chromo-
somal translocations are known to influence expression 
of local genes. MALAT1 plays a critical role in maintain-
ing the proliferation potential of early-stage hematopoi-
etic cells [14]. MALAT1 is differentially regulated during 
the activation of B-cells, and recent reports implicate it 
as a target of activation-induced deaminase (AID), which 
can induce oncogenic translocations in germinal center 
B-cells [15]. The expression level of MALAT1 is corre-
lated with tumorigenesis and metastasis in solid cancers 
and multiple myeloma, suggesting a universal cancer role 
[16]. Despite many previous studies, the role of MALAT1 
in lymphoma is not yet fully understood. In this study, we 




Mantle cell lymphoma patients’ samples and clinical 
information were collected and published under The 
University of Texas MD Anderson Cancer Center IRB-
approved clinical protocol LAB08-0190 for use of human 
tissues, with the written informed consent of all patients. 
Information about the patients is shown in Additional 
file  1: Table S1. Normal B lymphocytes were isolated 
from peripheral blood of healthy donors’ blood, obtained 
from Gulf Coast Blood Center (Houston, TX, USA), with 
CD19+  magnetic beads and released with DETACHa-
BEAD CD19 (Invitrogen, Grand Island, NY, USA).
Cell culture
Mantle cell lymphoma cell lines (Mino and Jeko-1) were 
obtained from ATCC (Manassas, VA, USA). Cell lines 
were regularly tested for mycoplasma (Lonza MycoAlert) 
and authenticated at the Cell Line Core Facility at MD 
Anderson Cancer Center, University of Texas, Houston, 
TX, USA. The cell lines were cultured in RPMI 1640 
medium with 10% fetal bovine serum (FBS, Gibco). The 
human cell lines were validated based on short tandem 
repeats (STR). STR repeats are regions of microsatellite 
instability with defined tri- or tetrad-nucleotide repeats 
that are located throughout the chromosomes. PCR reac-
tions using primers on non-repetitive flanking regions 
generate PCR products of different sizes based on the 
number of repeats in the region; the size of these PCR 
products are determined by capillary electrophoresis. 
This is performed by core facility at MD Anderson cancer 
center.
RNA isolation and quantitative real‑time PCR
Total RNA was extracted from patients MCL tissue or 
cell lines using RNeasy kit (QIAGEN) according to the 
manufacturer’s instructions. Reverse transcription reac-
tions were performed using a SuperScript III reverse tran-
scriptase kit (Invitrogen-Life Technologies) according to 
the manufacturer’s protocol. Quantitative real-time RT-
PCR was performed in triplicate using the StepOnePlus 
Real-Time PCR System (Applied Biosystems-Life Technol-
ogies) with TaqMan Universal PCR Master Mix accord-
ing to the manufacture’s protocol (Applied Biosystems). 
The TaqMan Gene Expression Assays (probe and primers) 
were purchased from Invitrogen Life Technologies, includ-
ing MALAT1 (ID: Hs00273907), EZH2 (ID: Hs00544833), 
CDKN1A/p21 (ID: Hs00355782) and CDKN1B/p27 (ID: 
Hs01597588). Human GAPDH was used as endogenous 
control. StepOne software version 2.0 (Applied Biosys-
tems) was used to determine RNA expression levels.
RNA interference
Mantle cell lymphoma cell lines were transfected with 
Neo transfection (Invitrogen) using five human MALAT1 
siRNAs (si-MALAT1, Life Technologies): si-MALAT1 
No.1 (product ID: 272231), si-MALAT1 No.2 (product 
ID:272233), si-MALAT1 No.3 (product ID:272234), si-
MALAT1 235 (product ID:272235) and si-MALAT1 236 
(product ID:272236), or negative control siRNA (si-NC, 
product ID: AM4635; Life Technologies). Transfection 
was performed three times to confirm results. Briefly, 
MCL cells were resuspended in Buffer R (Invitrogen) 
and mixed with a siRNA. Each 100 μL aliquot contained 
2 × 106 cells and 1 nmol of siRNA. After electroporation 
with program parameters (1550 V, 10 ms, 3 pulses) cells 
were cultured in RPMI 1640 and 10% FBS without anti-
bodies. Quantitative real-time PCR was performed to 
evaluate expression levels of MALAT1 using total RNA 
extracted 48  h after transfection (si-NC, si-MALAT) in 
Mino and Jeko-1 cells.
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Evaluation of proliferation, apoptosis and colony 
formation assay
Cell viability was measured 24, 48 and 72 h after trans-
fection with MTT assay kit (Promega, Madison, WI). 
Flow cytometry analysis for apoptosis was performed 
using Annexin V-FITC Apoptosis Detection Kit 48  h 
after transfection according to the manufacturer’s pro-
tocol (Sigma–Aldrich). All experiments were performed 
in triplicate. The colony formation assay was performed 
as described previously [17]. In brief, 5 × 104 cells were 
mixed with methylcellulose (H4100; Stemcell Tech-
nologies, Vancouver, BC, Canada) containing RPMI-
1640  +  10% FBS and poured in 35  mm plate. The 
colonies were allowed to grow for 7–14 days, followed by 
staining with p-Iodonitrotetrazolium violet and counted 
using Fluorchem 8800 imaging system (Alpha-Innotech, 
San Leandro, CA).
Cell synchronization and cell cycle analysis
Mino and Jeko-1 cells were synchronized to G2/M phase 
by treatment with nocodazole (Selleckchem). To syn-
chronize cells in G1, the synchronized G2/M cells were 
washed with PBS and grown in fresh medium for 12  h. 
Briefly, Mino and Jeko-1 cells were collected 24  h after 
transfection, and treated with 50  ng/ml nocodazole for 
24 h, then released in fresh medium. Cells were collected 
at 12 and 18 h after release and processed to ethanol fix-
ing (70% ethanol, ice-cold), RNase A-pretreating (0.5 mg/
ml at 37  °C for 30  min) and propidium iodide staining 
(50 μg/ml). Cell-cycle progression was measured by flow 
cytometry.
RNA immunoprecipitation assay
RNA immunoprecipitation (RIP) was performed using a 
Magna RIP RNA-Binding Protein Immunoprecipitation 
Kit (Millipore) according to the manufacturer’s instruc-
tions. Antibodies EZH2 (#5246; Cell Signaling Technol-
ogy) and SUZ12 (#3737; Cell Signaling Technology) used 
in RIP assays were diluted as 1:100. The coprecipitated 
RNAs were transcribed to cDNA, and detected by quan-
titative real-time RT-PCR using TaqMan Gene Expres-
sion Assays (Invitrogen Life Technologies).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) was performed 
using the EZ-ChIP Chromatin Immunoprecipitation 
Kit (Millipore) according to the manufacturer’s instruc-
tion. Briefly, cross-linked chromatin was sonicated on 
a Branson Sonifier 150 at setting 4 with 15  s pulses six 
times on ice. Then, the chromatin was immunopre-
cipitated using anti-EZH2 (#5246; Cell Signaling Tech-
nology) or anti-H3K27me3antibodies (#17-622, EMD 
Millipore). The quantitative real-time PCR was used to 
detect immunoprecipitated DNA using SYBR Green 
PCR Master Mix (Applied Biosystems) according to the 
method described above. Primers were used to iden-
tify promoter domain in immunoprecipitated DNA: 
CDKN1A/p21 (5′-TCTGGGGTCTCACTTCTTGG-3′; 
5′-ATGTGAGGAAGGCTCAGTGG-3′) and CDKN1B/
p27 (5′-GATGGGGTTCACCGTGTTAG-3′; 5′-CCCTT 
TCCAAACATCCATTG-3′).
Western blot analysis
Western blot analysis was performed as previously 
described [8, 18]. The antibodies used were specific for 
p21 Waf1/Cip1 (#2947, Cell Signaling Technology), p27 
Kip1 (#2552, Cell Signaling Technology), EZH2 (#5246; 
Cell Signaling Technology), H3K27me3 (#39155, Active 
Motif ), Histone H3 (#9715, Cell Signaling Technol-
ogy) and pEZH2 T345 (#61241, Active Motif, recognize 
human pEZH2 T350). Anti-β-actin horseradish per-
oxidase antibody (1:10,000; Sigma Aldrich, Buchs, Swit-
zerland) was used as loading control. Visualization was 
achieved by Supersignal West Pico chemiluminescent (or 
Femto Maximum Sensitivity) substrate (Pierce).
Statistical analysis
Experimental data are presented as mean  ±  SD from 
three independent experiments, unless otherwise indi-
cated. Differences between groups were calculated using 
the two-tailed Student’s t test (GraphPad Prism, La Jolla, 
CA, USA). Correlation between MALAT1 mRNA and 
EZH2 mRNA expression in human MCL tissues was 
examined with two-sided Pearson correlation. Over-
all survival was estimated with Kaplan–Meier method. 
P < 0.05 was considered statistically significant.
Results
Clinical correlation between MALAT1 expression 
and overall survival in MCL patients
First, we quantified MALAT1 expression level in 40 
MCL samples and peripheral CD19+  B lymphocytes 
from 12 healthy donors by quantitative real time poly-
merase chain reaction (qRT-PCR), and the average of 
MALAT1 levels in the healthy donors was normal-
ized to 1. MALAT1 expression was significantly higher 
in MCL tissue compared to healthy donor CD19  +  B 
lymphocytes (P  <  0.05; Fig.  1a). The Mantle Cell Lym-
phoma International Prognostic Index (MIPI) has been 
recently generated as a prognostic tool. Its scoring is 
based on a model using four clinical variables [19]. The 
40 MCL patients were divided into two groups using the 
median MIPI score of 5.8 as cutoff. We found that the 
MALAT1 expression level were closely associated with 
MIPI (P  <  0.05; Fig.  1b), and significantly higher in the 
high and intermediate risk groups compared to the low 
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risk group of MIPI (Additional file 1: Table S1) [19]. Next, 
we divided the MCL patients into two groups according 
to MALAT1 expression levels, using a median MALAT1 
2−ΔCt value of 21.1668. Then the association between 
the MALAT1 expression level and overall survival was 
assessed through Kaplan–Meier analysis and log-rank 
test. Results showed MALAT1 high expression group 
had significant shorter overall survival than MALAT1 
low group (P < 0.05; Fig. 1c).
Effect of MALAT1 on MCL cell proliferation, apoptosis, 
and cell cycle progression
The basal expression level of MALAT1 was determined 
in six mantle cell lymphoma derived cell lines (Z-138, 
Mino, REC-1, Jeko-1, JVM2 and Granta-519) (Additional 
file 2: Figure S1), the MCL cells with higher expression of 
MALAT1 (Mino and Jeko-1) which were used for addi-
tional experiments. Transient transfection was conducted 
with si-MALAT1 using electroporation on Mino and 
Jeko-1 cells. The knockdown effect was most profound 
using si-MALAT1 No.1 compared with si-MALAT1 
No.2 and No.3, which caused 96.1 and 66% decrease 
of MALAT1 levels in Mino and Jeko-1 cells, respec-
tively (Fig.  2a). si-MALAT1 236, decreased MALAT1 
expression in Mino and Jeko-1 cells (Additional file  3: 
Figure S2a). Thus, si-MALAT1 No.1 and si-MALAT1236 
were chosen for further experiments. To evaluate the 
effects of MALAT1 deletion on tumor cell proliferation, 
we used MTT and colony formation assays. As shown 
in Fig.  2, we observed significantly reduced cell viabil-
ity after MALAT1 knockdown. Compared to the si-NC 
groups, the cell viability of Mino and Jeko-1 cells trans-
fected with si-MALAT1 was decreased by 33.6 and 27.6% 
after 72  h of incubation, respectively (P  <  0.01; Fig.  2b; 
Additional file 3: Figure S2b). In addition, we found that 
si-MALAT1 transfected Mino cells were less clonogenic 
in methylcellulose compared to si-NC cells (Additional 
file  4: Figure S3), and the size of individual colonies 
Fig. 1 MALAT1 was over-expressed in MCL and is associated with clinical parameters. a Relative MALAT1 expression in primary human MCL tissues 
and CD19 + B lymphocyte from health donors, measured by qRT-PCR and normalized to gene expression levels of GAPDH. b The expression of 
MALAT1 was significantly higher in patients with high MIPI. c Kaplan–Meier plot of patients according to MALAT1 expression. Patients with high 
MALAT1 expression levels (n = 20) had a significantly lower overall survival than those with low expression (n = 20). Hazard ratio: 3.006 (95% CI: 
1.012 to 8.299) Data represent the mean ± SD. *P < 0.05
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was also significantly smaller in si-MALAT1 MCL cells 
(P < 0.01; Fig. 2c; Additional file 4: Figure S3b). Moreover, 
the percentage of apoptotic cells was increased 48 h after 
transfection with si-MALAT1 in Mino and Jeko-1 cells, 
respectively (P  <  0.01; Fig.  2d; Additional file  5: Figure 
S4, Additional file  6: Figure S5). Next, we explored the 
effect of MALAT1 on cell cycle progression. Mino and 
Jeko-1 cells could not be arrested in G0 by serum starva-
tion, perhaps due to the absence of a quiescent state in 
MCL cells. Then, we synchronized Mino and Jeko-1 cells 
in G2/M phase with nocodazole and released them with 
or without MALAT1 knockdown at different time points 
(12 and 18  h after release) and examined the cell cycle 
progression (Additional file  7: Figure S6). We observed 
cell cycle arrest at the S/G1 transition in si-MALAT1 
transfected MCL cells (Mino and Jeko-1) (Fig. 2e; Addi-
tional file 7: Figure S6b, Additional file 8: Figure S7).
MALAT1 binding to polycomb repressive complex 2 (PRC2) 
through EZH2
Previous studies have revealed that several lncRNAs, 
such as HOTAIR and Xist, bind to PRC2 enhancing tri-
methylation of histone H3 on lysine 27 (i.e. H3K27me3), 
that results in epigenetic silencing of target gene [20]. 
It was reported that MALAT1 also affect gene expres-
sion by interacting with PRC2 through different subu-
nits (EZH2, SUZ12) [21, 22]. To investigate whether 
there is an interaction between MALAT1 and PRC2 in 
MCL, we performed RIP with antibodies against EZH2 
or SUZ12. It is apparent that MALAT1 was significantly 
enriched with the EZH2 antibody and not with SUZ12 
antibody and IgG (control antibody) in two MCL cell 
lines; P  <  0.001; Fig.  3a–d). The expression levels of 
MALAT1 and EZH2 were compared in MCL samples, 
and we observed that there was a notable positive cor-
relation between these two groups (Pearson correlation, 
r = 0.4361, P < 0.01; Fig. 3e).
Association of EZH2 with clinical parameters in MCL
In same cohort of patients, we found the expression of 
EZH2 was significantly elevated in MCL tissues com-
pared with healthy donors (P  <  0.01; Fig.  3f ). To fur-
ther investigate the prognostic value of EZH2 on MCL, 
patients were divided into two groups according to EZH2 
expression levels, using a median EZH2 2−ΔCt value of 
0.0292 as cutoff. We found expression level of EZH2 was 
significantly higher in high and intermediate risk groups 
compare to low risk group classified according to MIPI 
(P  <  0.01; Additional file  9: Table S2) [19], and overall 
survival was also significantly lower in the high EZH2 
expression group compared with the low group (P < 0.01; 
Fig. 3g).
MALAT1 represses the expression of PRC2‑dependent 
target genes by associating with EZH2
It was reported that TUG1 was associated with PRC2, 
resulting in the epigenetic repression of cyclin-depend-
ent protein kinase inhibitors, including p21 and p27, thus 
contributing to the regulation of cell cycle and prolifera-
tion in germinal center B (GCB) cells [23]. CDKN1A/p21 
and CDKN1B/p27 have also been reported to be EZH2 
target genes in lymphoma cell line SUDHL4, and sup-
pressed by H3K27-trimethylation [24]. To investigate 
whether expression of the CDKN1A/p21 and CDKN1B/
p27 were affected by MALAT1 in MCL, we analyzed 
p21and p27 expression after MALAT1 knockdown. As 
expected, the mRNA level of CDKN1A/p21 (P  <  0.01; 
Fig.  4a) and CDKN1B/p27 (P  <  0.01; Fig.  4b) were sig-
nificantly increased in si-MALAT1 transfected MCL cell 
lines Mino and Jeko-1. A higher protein level of p21 and 
p27 in MALAT1 knockdown cells was observed (Fig. 4c; 
Additional file  10: Figure S8). Meanwhile, expression 
of EZH2 and H3K27me3 protein was decreased after 
MALAT1 knockdown in MCL cell lines (Fig.  4d; Addi-
tional file 10: Figure S8).
Our data shows that EZH2 binds directly to MALAT1 
and enhances EZH2-mediated H3K27me3 and gene 
repression. To further determine whether MALAT1 
increases EZH2 recruitment and H3K27me3 levels at 
EZH2 target loci, we performed a ChIP assay using 
anti-EZH2 and anti-H3K27me3 antibodies in MCL cells 
treated with si-MALAT1 or si-NC. The ChIP assay dem-
onstrated that MALAT1 knockdown decreased EZH2 
recruitment to the promoters of target genes CDKN1A/
p21 and CDKN1B/p27 in Mino and Jeko-1 cells (Fig. 5a, 
b). Meanwhile, similar results were observed when we 
determined the levels of H3K27me3 at these gene pro-
moters in both cell lines (Fig. 5c, d). These results indi-
cate that MALAT1 represses expression of CDKN1A/
p21 and CDKN1B/p27 by recruiting EZH2 and enhanc-
ing the H3K27me3 activity.
EZH2 binding with MALAT1 can be self‑enhanced 
by associating with p21/p27 and phosphorylation of EZH2
Some reports have demonstrated that cyclin-dependent 
kinase (CDK) 1 and CDK2 can induce phosphoryla-
tion of EZH2 at threonine 350 (T350) which increased 
the binding to lncRNAs, such as HOTAIR and XIST, 
thus further facilitating recruitment of PRC2 to its tar-
get genes [25–27]. To investigate whether EZH2 can be 
phosphorylated at T350 by CDKs in MCL cells, Mino 
and Jeko-1 cells were treated for 12  h with the CDKs 
inhibitor (roscovitine, 25  μM). Western blot results 
showed the phosphorylation of EZH2 at T350 was inhib-
ited with roscovitine (Fig.  6a). To further determine 
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Fig. 2 Knockdown of MALAT1 inhibited malignant potential of MCL. a Knockdown of MALAT1 with si-MALAT1(No.1, No.2 and No.3) and nontarget 
control analyzed by qRT-PCR. b Cell viability assay on MCL cells transfected with si-MALAT1 or si-NC. c Colony formation assay. The number of colo-
nies significantly decreased, and the size of individual colonies were significantly reduced in MALAT1 knockdown Mino cells. d Apoptosis in MCL 
cells transfected with si-MALAT1 or si-NC was detected by flow cytometry after annexin V/PI staining. e Cell cycle analysis by flow cytometry. Ratio 
of percentage of cells in S phase to G1 phase was significantly decreased in MALAT1 knockdown MCL cells (Mino and Jeko-1). Data are representa-
tive of three independent experiments and represent the mean ± SD
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whether the phosphorylation of EZH2 at T350 influ-
ence binding to MALAT1, we performed RIP analysis. 
Results revealed that binding of MALAT1 with EZH2 
significantly decreased with absence of T350 phospho-
rylation due to roscovitine treatment (Mino and Jeko-
1; P  <  0.01; Fig.  6b). As our data shows that MALAT1 
represses the expression of CDKs inhibitors, p21 and 
p27, we sought to determine whether MALAT1 knock-
down could change the phosphorylation of EZH2 at 
T350. As expected, Western Blot analysis demonstrated 
that the levels of pT350-EZH2 decreased in MALAT1 
knockdown MCL cells (Fig.  6c). To determine whether 
the decrease of pT350–EZH2 was due to change of total 
EZH2, the band on Western blot was quantified. We 
found that pT350–EZH2 levels decreased after normali-
zation to total EZH2 in MALAT1 knockdown MCL cells 
(Fig. 6d).
Our results suggest that deletion of MALAT1 inhibits 
recruitment of PRC2 to target genes loci, which further 















Fig. 3 Correlation between MALAT1 and EZH2 in MCL. a–d RNA immunoprecipitation in Mino and Jeko-1 cells. a Input and immunoprecipitate 
from rabbit IgG and anti-EZH2 antibody bond beads, detected by immunoblotting with EZH2 antibody, b Input and immunoprecipitate from rabbit 
IgG and anti-SUZ12 antibody bound beads, detected by immunoblotting with SUZ12 antibody, using Western blot analysis. c, d qPCR showing 
MALAT1 is significantly enriched in the immunoprecipitate from the EZH2 antibody bound beads compared to SUZ12 and IgG (control antibody) in 
(c) Mino and (d) Jeko-1 cells. e Pearson’s correlation between MALAT1 mRNA and EZH2 mRNA expression (2−delta Ct value) in MCL. f Relative MALAT1 
expression in MCL clinical samples and CD19 + B lymphocyte from healthy donors, measured by qRT-PCR and normalized to gene expression levels 
of GAPDH. g Overall survival of MCL patients with high and low EZH2 expression (Kaplan–Meier plot). Patients with high EZH2 expression levels 
(n = 20) had significantly lower overall survival than those with low expression (n = 20). Hazard ratio: 3.977 (95% CI: 1.512 to 13.01). Data represent 
the mean ± SD.**P < 0.01
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thereby inducing cell cycle arrest and reduces T350 phos-
phorylated EZH2, and further resulting in weaker bind-
ing to MALAT1 (Fig. 7b).
Discussion
Previous studies have reported high expression of 
lncRNA MALAT1 in solid tumors and hematologic 
malignancies and hinted to its role on transcription 
complexes [16]. Here we showed that MALAT1 is over-
expressed in MCL tissues, which correlates with high 
MIPI and poor overall survival of MCL patients. Silenc-
ing of MALAT1 expression inhibited cell proliferation 
and increased apoptosis rates of MCL cells. In addition, 
we observed that down-regulation of MALAT1 increased 
expression of p21 and p27 through an EZH2-associated 
mechanism. Moreover, decreased phosphorylation of 
EZH2 at T350 attenuated its binding to MALAT1. Col-
lectively, our results implicate MALAT1 as a mechanistic 
and prognostic marker for MCL.
MALAT1 has been found to be up-regulated in several 
types of solid tumors [16]. Our study investigated MCL, 
an aggressive type of non Hodgkins lymphoma, and 
found that the expression of MALAT1 was significantly 
higher in MCL compared to normal B-cells (P  <  0.01). 
We additionally identified that the increased expression 
of MALAT1 was associated with high-risk group (by 
MIPI) and lower overall survival after current chemo-
therapy in patients with MCL. We probe for the role of 
MALAT1 using knockdown approach. After siRNA-
mediated knockdown of MALAT1, cell proliferation was 
decreased and the percentage of apoptotic cells was sig-
nificantly increased in MCL cells (P < 0.01). MALAT1 in 
another hematological cancer, multiple myeloma (MM) 
has been shown to also target latent transforming growth 
factor beta-binding protein 3 (LTB3) and suggest that 
MALAT1 may have widespread effects across differ-
ent transcription complexes [28–30]. Mechanistically, 


















Fig. 4 Effect of MALAT1 knockdown on the expression of EZH2 and H3k27me3, and cell cycle regulators p21 and p27. a, b qRT-PCR results for 
expressions of CDKN1A/p21 and CDKN1B/p27 (si-NC vs si-MALAT1). c, d The expression of EZH2 and H3k27me3 were suppressed, while p21 and 
p27 were increased in MALAT1 knockdown cells by Western blot analysis
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promoter of LTBP3, thereby resulting in elevated level 
of LTBP3 transcription and TGF-β1 secretion, which 
plays a role in the suppression of bone formation in MM 
bone lesions [29]. MALAT1 was also found associated 
with molecular pathways involving cell cycle regulation, 
p53-mediated DNA damage response, and mRNA matu-
ration processes in MM using microarray analysis [30].
Our immunoprecipitation experiments revealed nota-
bly high affinity of binding between MALAT1 and EZH2, 
rather than SUZ12 in MCL. Recent studies reported that 
several lncRNAs (such as HOTAIR, Xist, and H19) act 
to repress genes by binding PRC2 [31–34]. Further stud-
ies of over 3300 lncRNAs identified that about 20% of 
these lncRNAs are binding partners for PRC2 [35]. Nota-
bly, binding of lncRNA to PRC2 is size dependent, with 
higher affinity belonging to longer RNAs [36]. In line 
with this, lncRNA MALAT1, with a large size (∼8000 
nt), has been found to interact with PRC2 through EZH2 
or SUZ12. Specifically, EZH2 mediates the role of the 
MALAT1–PRC2 partnership in the epithelial–mesen-
chymal transition in renal cell carcinoma [22], whereas 
SUZ12 promotes the role of the MALAT1-PRC2 binding 
in tumor metastasis in bladder cancer [21].
Our results showed that the EZH2 mRNA expression 
was significantly higher in primary MCL tissues com-
pared to normal B-cells (P < 0.01). Patients with a higher 
level of EZH2 expression had lower overall survival as 
compared to those with low EZH2 expression. Our data 
showed that there was a significant positive correlation 
between MALAT1 and EZH2 mRNA in MCL. Using 
Basso’s Lymphoma dataset from Oncomine database, we 
previously showed that EZH2 mRNA is highly expressed 
in lymphomas compared to healthy donor’s B-lympho-
cytes [8]. Independent of tumor proliferation, the expres-
sion level of EZH2 was identified as a prognostic factor 
in MCL, using multivariate survival analysis [37]. Thus, 
we sought to determine the underlying molecular mech-
anisms by which MALAT1 functions in concert with 
EZH2 to regulate downstream effector in MCL.
Through EZH2-mediated mechanisms, PRC2 cata-
lyzes the trimethylation of histone H3 on lysine 27 (i.e. 
H3K27me3) to repress transcription of specific genes. 
Upregulation of EZH2 leads to silencing of the genes that 
are involved in the progression and metastasis of solid 
tumors [38, 39], and malignant hematopoiesis and lym-







Fig. 5 P21 and p27 expression were repressed by MALAT1 associating with EZH2. a, b ChIP analysis of Mino (a) and Jeko-1 (b) cells transfected with 
si-NC and si-MALAT1 were conducted on CDKN1A/p21 and CDKN1B/p27 promoter regions using anti-EZH2 antibody. c, d ChIP-qPCR analysis of 
H3k27me3 levels at the promoters of CDKN1A/p21 and CDKN1B/p27 using si-NC and si-MALAT1 transfected cells, Mino (c) and Jeko-1 (d). Data are 
mean ± S.D. from experiments with three replicates. **P < 0.01, ***P < 0.001
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after knockdown of MALAT1, the levels of EZH2 and 
H3K27me3 expression were both decreased, whereas 
that of p21 and p27 were increased at both mRNA and 
protein levels, resulting in cell cycle arrest at G1/S tran-
sition. p21 and p27 are both CDKs suppressors involved 
in regulating cell cycle progression, and have also been 
considered as candidates for tumor-suppressor genes. 
Reduced expression of p21 or p27 has shown to be cor-
related with increased malignancy, high Ki-67 index and 
poor prognosis in MCL patients [37, 41, 42]. Upregula-
tion of EZH2 was related with cell proliferation in the 
development of B lymphocyte, and tumor suppressor 
genes, CDKN1A/p21 and CDKN1B/p27, were histone-3 
lysine27-trimethylated and repressed in those proliferat-
ing GC-B-cells [24]. And siRNA-mediated knockdown 
of EZH2 increased the mRNA expression of CDKN1A/
p21 and CDKN1B/p27, leading to cell cycle arrest at 
G1/S transition in DLBCL and MCL cell lines [24, 43]. 
Consistently, in several solid tumors (such as prostate 
cancer, ovarian cancer and lung cancer), CDKN1A/p21 
and CDKN1B/p27 were identified as EZH2 targets by 
ChIP-qPCR analysis, and inhibited due to elevated level 
of EZH2 [44–47].
Intriguingly, some reports have identified an important 
role for MALAT1 in regulating p21 and p27, potentially 
mediated by p53 [48, 49]. However, no p53 knockdown 
experiments were carried out to directly show that 
whether p53 is the only mediator of p21 regulation by 
MALAT1 [48]. Indeed, another report found no cor-
relation between the expression of p21 and p53 in MCL 
patients, suggesting the possibility of p53-independent 
mechanisms underlying MALAT1-mediated regulation of 
p21 [50]. A recent study demonstrated that p21 regulation 
is determined by the methylation and acetylation status of 
histone H3 on the p21 (WAF-1) promoter in lymphoma 
[51]. These previous observations lead to our hypothesis 
that p21 and p27 are regulated by MALAT1 through an 




























































Fig. 6 MALAT1 facilitated phosphorylation of EZH2 at T350, which up-regulated MALAT1-binding activity. a The effect of CDK inhibitors on EZH2 
phosphorylation. Immunoblot analysis of pT350-EZH2, total EZH2 in Mino and Jeko-1 cells following 12 h treatment with roscovitine (25 μM). b, c 
Results from qRT-PCR of MALAT1 bound to EZH2 in Mino (b) and Jeko-1 (c) cells. Signals were normalized by the total amount of MALAT1 mRNA in 
each case. d Western blot results revealed the expression of both total EZH2 and pT350-EZH2 significantly decreased in Mino and Jeko-1cells trans-
fected with si-MALAT1. Phosphorylation of EZH2 at Thr 350 was inhibited in MALAT1 knockdown cells, normalized to total EZH2
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In the present study, our ChIP analysis demonstrated 
that EZH2 occupancy and H3K27me3 level at the pro-
moter domains of p21 and p27 were both significantly 
decreased in MALAT1-deficient cells compared with 
control cells (P  <  0.01), suggesting that overexpressed 
MALAT1 down-regulates p21 and p27, a process possi-
bly mediated by EZH2-driven H3K27me3 in MCL. Con-
sistent with our results, EZH2 depletion by either DZNep 
or siRNA induced the expression of p21 and p27 in MCL 
cell lines [43].
It has been established that CDK1 and CDK2 phos-
phorylate EZH2 at T350, which is important for its 
binding to lncRNAs, HOTAIR and XIST, and recruit-
ment of the PRC2 complex to the EZH2 target genes 
[25–27]. Our results suggested that the phosphorylation 
of EZH2 at T350 affected its binding to lncRNA 
MALAT1. This is consistent with a previous study 
showing that lncRNA MALAT1 preferentially binds to 
EZH2 in two regions (amino acids 1–173 and 336–554), 
including the phosphorylation site T350 [52]. In the 
present study, we initially observed that the phospho-
rylation of EZH2 at T350 was consistently reduced after 
treatment with CDKs inhibitor roscovitine. To confirm 
consequence of reduced phosphorylation of EZH2 at 
T350, our RIP results show decreased EZH2–MALAT1 
binding.
Our results showed that the phosphorylation of EZH2 
at T350 was inhibited in MALAT1-deficient MCL 
cells. This could be a result of elevated expression of 
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Fig. 7 Schematic diagram illustrating signaling of MALAT1 and its downstream effectors in MCL. a LncRNA MALAT1 recruits PRC2 to target genes 
through binding to EZH2. Then, CDKN1A/p21 and CDKN1B/p27 expression is epigenetically repressed by H3K27me3. Then, activated CDK1 and 
CDK2 promotes phosphorylation of EZH2 at T350, resulting in increase binding to MALAT1. b Low expression or knockdown of MALAT1 decrease 
the recruitment of PRC2 to targeted genes p21 and p27, which inhibit CDKs activities, causing cell cycle arrest and decreased phosphorylation of 
EZH2 at T350. Finally, EZH2 with low T350 phosphorylation further inhibits its MALAT1-binding activity
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these observations, we propose a hypothesis of posi-
tive feedback loop. Specifically, up-regulated expression 
of MALAT1 leads to the recruitment of EZH2 to target 
gene loci, thus enhancing EZH2-mediated H3K27me3 
and suppressing the expressions of p21 and p27 (Fig. 7b). 
This leads to the activation of CDK1 and CDK2 that pro-
mote the phosphorylation of EZH2 at T350, which fur-
ther increases the binding of EZH2 with MALAT1. This 
increased binding in turn enhances EZH2-mediated 
H3K27me3 and gene repression (Fig.  7b). Given that 
CDK1 and CDK2 are highly activated at the S and G2 
phase, we envision a model that CDK-induced phospho-
rylation of EZH2 would probably become decreased at 
the other phase of the cell cycle in normal cells, which 
might facilitate the expression of EZH2 target genes and 
thereby promote cell differentiation. In MCL cells, CDKs 
are constantly activated due to the repression of p21 and 
p27 genes by overexpressed lncRNA MALAT1, thereby 
activating EZH2 to induce uncontrolled cell proliferation. 
We showed that deletion of MALAT1 with siRNA inter-
feres with this postulated positive feedback loop, result-
ing in cell cycle arrest.
This study shows that overexpression of the lncRNA 
MALAT1 provides some oncogenic properties, and may 
be a prognostic factor or therapeutic target in MCL. 
MALAT1 expression is significantly higher in MCL tis-
sues than normal tissues (P  <  0.01). This may be asso-
ciated with the key translocation of MCL t (11;14) 
(q13;q32), the breakpoint of which is adjacent to the 
MALAT1 gene loci 11q13. Further experiments are 
required to delineate this hypothesis. Our study also 
needs to be interpreted with cautions due to the lack of 
in vivo experiments. Future experiments with appropri-
ate animal models may be helpful to clearly understand 
the underlying molecular mechanism in MCL progres-
sion. Small interfering RNA is a good choice for delet-
ing lncRNAs, which locate in the cytoplasm. But for 
suppressing nuclear lnRNAs, such as MALAT1 and 
NEAT1, it is more effective to use antisense oligonucle-
otides (ASOs) [53]. Preclinical studies have shown the 
therapeutic efficacy of ASOs targeting MALAT1 in the 
mouse MMTV–PyMT breast cancer model. Systemic 
knockdown of MALAT1 through subcutaneous injec-
tion of ASOs inhibits tumor proliferation and metas-
tasis, and induces differentiation [54]. Moreover, RNA 
depletion is not the only way to inhibit lncRNA func-
tion. Using steric blocking oligonucleotides, lncRNAs 
may be blocked to interact with their binding partners, 
such as protein, DNA and miRNA [55]. Future technical 
innovations will offer more effective lncRNA-targeting 
therapeutics.
Conclusions
We first report that MALAT1 is highly expressed in 
MCL cells and correlated with clinic characters including 
patient outcome. After MALAT1 knockdown, cell prolif-
eration was inhibited and apoptosis rate was increased in 
MCL cell lines, suggesting that MALAT1 could function 
as a potential oncogene in MCL. Our results clearly dem-
onstrate that knockdown of MALAT1 reduced EZH2 
level and recruitment to the target gene (p21 and p27), 
resulting in cell cycle arrest at G1/S transition. We subse-
quently show that MALAT1-induced EZH2 recruitment 
is self-enhanced through EZH2 phosphorylation at T350 
in MCL. Above all, MALAT1 may be used as a prognos-
tic factor or therapeutic target in MCL.
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Additional file 3: Figure S2. Knockdown of MALAT1 inhibited prolifera-
tion of MCL. a Knockdown of MALAT1 with si-MALAT1(No.235 and 236) 
and nontarget control analyzed by qRT-PCR. b Cell viability assay using 
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tosis. Apoptosis in MCL cells transfected with si-MALAT1 No. 236 or si-NC 
was detected by flow cytometry after annexin V/PI staining.
Additional file 7: Figure S6. Knockdown of MALAT1 and cell cycle 
profile. Cell cycle analysis of control (si-NC) and MALAT1 knockdown 
cells (si-MALAT1) post-mitotic release. a Transfected MCL cells (Mino and 
Jeko-1) were treated with nocodazole for 24 hours for synchronization 
and examined for G1/S progression 18 hours after released. b Cell cycle 
analysis of control and MALAT1 knockdown cells by flow cytometry.
Additional file 8: Figure S7. Cell cycle analysis by flow cytometry. 
Ratio of cell percentage in S phase to G1 phase significantly decreased in 
MALAT1 knockdown MCL cells (Mino and Jeko-1). Data are representative 
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Additional file 10: Figure S8. Effect of MALAT1 knocking down on the 
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Jeko-1) as analyzed by Western blot.
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